Friends, Parker Institute call for more flexibility in early T cell therapy development

Friends of Cancer Research and the Parker Institute for Cancer Immunotherapy recommend more flexible IND and manufacturing requirements and the use of adaptive clinical trials to advance development of emerging cellular therapeutics such as CAR T and engineered T cell receptor (TCR) therapies.

In a white paper, the institutions recommended early

Read the full 507 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE